Neuralstem (CUR) Getting Somewhat Positive Press Coverage, Study Shows

Media headlines about Neuralstem (NASDAQ:CUR) have been trending somewhat positive this week, AlphaOne Sentiment Analysis reports. The research firm, a unit of Accern, identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Neuralstem earned a media sentiment score of 0.04 on AlphaOne’s scale. AlphaOne also gave media stories about the company an impact score of 91 out of 100, meaning that recent news coverage is extremely likely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted AlphaOne Sentiment’s rankings:

Separately, S&P Equity Research lowered their price objective on shares of Neuralstem from $3.69 to $3.18 in a research report on Thursday, February 16th.

Shares of Neuralstem (NASDAQ CUR) traded up 6.8188% during mid-day trading on Wednesday, reaching $4.5398. 26,275 shares of the company’s stock traded hands. Neuralstem has a 12-month low of $2.47 and a 12-month high of $6.19. The stock’s market cap is $54.02 million. The firm’s 50 day moving average price is $4.53 and its 200-day moving average price is $3.26.

In other Neuralstem news, CFO Jones Jonathan Brian Lloyd acquired 5,455 shares of the stock in a transaction dated Friday, March 24th. The shares were purchased at an average price of $5.50 per share, for a total transaction of $30,002.50. Following the purchase, the chief financial officer now directly owns 7,859 shares of the company’s stock, valued at $43,224.50. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Richard J. Daly acquired 7,500 shares of the stock in a transaction dated Wednesday, May 17th. The stock was acquired at an average price of $4.00 per share, for a total transaction of $30,000.00. Following the purchase, the chief executive officer now directly owns 23,312 shares in the company, valued at $93,248. The disclosure for this purchase can be found here. 19.25% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Neuralstem (CUR) Getting Somewhat Positive Press Coverage, Study Shows” was originally reported by Mideast Time and is the property of of Mideast Time. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CUR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.